12 studies on TB-500 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 2,467 published TB-500 COA source records from third-party laboratories, covering 828 publicly attributable vendor identities. Across 2,090 records with positive numeric purity, the arithmetic mean is 98.97%. 35 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 20 positive purity results are below 90%; 111 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-16. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 4 mg | $10.50 | $10.50–$10.50 | $2.62 | 1 source · 1 offer |
| 5 mg | $10.33 | $9.50–$11.50 | $2.07 | 3 sources · 3 offers |
| 10 mg | $18.00 | $17.00–$18.50 | $1.80 | 4 sources · 4 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-16. Aggregate calculated: 2026-10-18T04:28:00.970024+00:00. Calculation time is not a laboratory observation date.
Within that total, 571 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 59 | 99.43% | 0 of 47 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified | Reveal with Pro → | |
| #2 | 36 | 99.32% | 0 of 29 (0.0%) 0 0% / not detected · 0 wrong compound · 7 unclassified | Reveal with Pro → | |
| #3 | 21 | 99.51% | 0 of 21 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120388 (99.6%) · #119568 (99.91%) · #120350 (99.17%) · #119631 · #119630 · #119475 (99.72%)
This review underscores the significant potential of therapeutic peptides in gerontological medicine, offering a novel approach to combat age-related diseases. By targeting fundamental aging mechanisms, peptides could…
This research is critically important for anti-doping efforts in sports, as it provides a definitive chemical signature for a suspected performance-enhancing substance. By identifying Ac-LKKTETQ as the active componen…
This review provides a crucial overview of the current challenges and solutions in anti-doping science. For athletes and support personnel, it reinforces the sophistication and reach of modern testing protocols, makin…
For athletes and individuals using performance-enhancing peptides, this review underscores that sophisticated detection methods are already established for a wide array of compounds, including popular research peptide…
For anti-doping analysts and forensic toxicologists, this study validates a practical and ethical method for identifying new biomarkers of peptide abuse. Instead of relying on difficult-to-conduct human trials, labs c…
For anti-doping agencies, this research provides a validated method to significantly increase the speed and efficiency of screening for peptides like the TB-500 fragment. The ability to process **up to 96 samples simu…
This research provides a clear roadmap for anti-doping laboratories on how to effectively study the metabolism of unapproved peptides. By identifying human kidney microsomes and liver S9 fractions as the most effectiv…
This research highlights a critical, often overlooked, factor in analytical accuracy for peptide quantification, particularly in sensitive areas like doping analysis and biopharmaceutical research. The findings unders…
Establishing a standardized chemical identity through resources like PubChem is foundational for all subsequent research into TB-500. It prevents ambiguity and ensures that studies conducted globally on this peptide a…
A Phase 1/2 trial is recruiting to assess TB-500's safety, tolerability, and pharmacokinetics, alongside exploratory cardiovascular biomarkers, in stable ASCVD patients.
This simplified and highly sensitive testing method significantly enhances the ability of anti-doping agencies to detect a wide range of prohibited peptides like AOD-9604. For athletes using or considering these compo…
Free, no account — handy when you're working with TB-500.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account